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Introduction
Menopause is defined as the permanent
cessation of menses resulting from reduced
ovarian hormone secretion that occurs naturally
or is induced by surgery, chemotherapy, or
radiation. Natural menopause is recognized after
12 months of amenorrhea that is not associated
with a pathologic cause. The average age of
menopause in the United States is 51 years, and
can vary normally between 40 and 58 years.1 The
menopausal transition can span over several years,
and often begins with variations in menstrual
cycle length in response to rising levels of follicle
stimulating hormone (FSH). The mean age of
onset of the menopausal transition is 47.5 years
and commonly lasts approximately 4 to 5 years.1
Stages and nomenclature of the menopausal
transition were defined by experts in 2001 at the
Stages of Reproductive Aging Workshop
(STRAW).2 The group recognized seven stages of
the reproductive aging continuum, and
acknowledged that most women do not progress
precisely through each stage. These stages are also
described by the following terms:
•

Premenopause: the time up to the beginning
of the perimenopause, but is also used to
define the time up to the last menstrual
period.

•

Perimenopause: the time around menopause
during which menstrual cycle and endocrine
changes are occurring but 12 months of
amenorrhea has not yet occurred.

•

Postmenopause: begins at the time of the last
menstrual period, although not recognized
until after 12 months of amenorrhea.

A hot flash or flush refers to the spontaneous
sensation of warmth, often associated with
perspiration, resulting from a vasomotor response
to declining estrogen levels. Nightsweats are hot
flashes or flushes occurring at night, often while
sleeping. Other symptoms, such as vaginal
dryness, sleep disturbance, mood symptoms,
cognitive disturbances, somatic complaints,
urinary complaints, uterine bleeding problems,
sexual dysfunction, and reduced quality of life are
also attributed to the menopausal transition.
Although many measures have been developed
to assess menopausal symptoms, few demonstrate
standardization, validity, or reliability. Some
measures are based on self-reports of the presence,
severity, and frequency of individual symptoms,
such as hot flashes. Others utilize cumulative or
global scores based on lists or scales of symptoms
attributed to menopause, such as mood,
cognition, quality of life, sexual function, and
somatic symptoms. Many studies base their
measures on study-specific checklists,
questionnaires, or scales. Ninety-two measures of
menopausal symptoms were reported by studies
included in this evidence review.

Purpose
This systematic evidence review focuses on five
Key Questions relating to symptoms of
menopause and their management, as specified by
the Planning Committee for the National
Institutes of Health State-of-the-Science
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Evidence-Based
Practice

Conference on Management of Menopause-Related Symptoms.
The target population includes adult women in the United
States undergoing the menopausal transition.
1. What is the evidence that the symptoms more frequently
reported by middle-aged women are attributable to
ovarian aging and senescence? These include vasomotor
symptoms, vaginal dryness, sleep disturbance, mood
symptoms, cognitive disturbances, somatic complaints,
urinary complaints, uterine bleeding problems, sexual
dysfunction, and reduced quality of life.
2. When do the menopausal symptoms appear, how long do
they persist and with what frequency and severity, and
what is known about the factors that influence them?
Factors include race and ethnicity, age at onset of the
menopause transition, body mass index (BMI), surgical
versus natural menopause, depression, and smoking.
3. What is the evidence for the benefits and harms of
commonly used interventions for relief of menopauserelated symptoms? Interventions include estrogens,
progestins, androgens, tibolone, antidepressants, other
drugs, phytoestrogens, complementary and alternative
medicine, and behavioral interventions.
4. What are the important considerations in managing
menopause-related symptoms in women with clinical
characteristics or circumstances that may complicate
decision-making? These include bilateral oophorectomy,
premature ovarian failure, breast cancer, concurrent use of
selective estrogen receptor modulators (SERMs) and other
interacting therapeutic agents, lifestyle and behavioral
factors, recent discontinuation of menopausal hormone
therapy, and very low or very high BMI.
5. What are the future research directions for treatment of
menopause-related symptoms and conditions?

Methods
A Technical Expert Panel was assembled to provide input
from experts and clinicians in the field to ensure that the scope
of the project addressed important clinical questions and issues.
The panel included obstetrician/gynecologists, internists,
naturopathic physicians, behavioral experts, and researchers.
The panel was convened for periodic conference calls during
the course of the project. Expert reviewers, including several
panel members, provided comments on the draft evidence
report.
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Literature Search and Strategy
Relevant studies were identified from multiple searches of
MEDLINE®, PsycINFO, DARE, the Cochrane database of
systematic reviews and controlled trials, MANTIS, and AMED
(1953 to November 2004); and from recent systematic reviews,
reference lists, reviews, editorials, websites, and experts.
Retrieved abstracts were entered into an electronic database
(EndNote®).
Inclusion and Exclusion Criteria
Full text cohort studies with data on women experiencing
menopause and at least one of the symptoms listed in Key
Question 1 were initially reviewed and subsequently included if
the study enrolled 100 or more subjects, subjects represented
the target population, and data on symptoms associated with
menopause were provided. Exclusions included studies of
women not undergoing the menopausal transition and
experiencing menopause related symptoms, studies of aging
and its effects, and biologically based studies that did not report
epidemiological data relating to symptoms (e.g., studies of
hormone levels). Non-English language papers and studies of
animals or cadavers were also excluded. Cross-sectional studies
meeting similar inclusion/exclusion criteria were examined for
contributory data and included if they reported relevant data
about symptoms by menopausal stage, such as prevalence rates.
Full text randomized controlled trials and meta-analyses of
randomized controlled trials providing data on treatment of
menopausal symptoms, using one or more of the interventions
listed in Key Question 3, were included. Trials enrolling
women with breast cancer were considered separately from
those enrolling women without breast cancer. Exclusions
included studies of women not undergoing menopause and
experiencing menopause related symptoms during the course of
the study, studies of animals, and non-English language papers.

Data Extraction and Synthesis
All eligible studies were reviewed and a “best evidence”
approach was applied, in which studies with the highest quality
and most rigorous design are emphasized.3 Data were extracted
from each study, entered directly into evidence tables, and
summarized descriptively. Benefits and adverse effects of
therapies were considered equally important and both types of
outcomes were abstracted. Trials of alternative and
complementary therapies were grouped according to the
National Center for Complementary and Alternative Medicine
categories4 most closely related to included topics. Results of

recently published meta-analyses on estrogens5-7 and isoflavones8
are included in this report. No new meta-analyses were
conducted because of heterogeneity of trials of other therapies.
Two reviewers independently rated the quality of
randomized controlled trials and cohort studies using criteria
specific to different study designs developed by the United
States Preventive Services Task Force.9 Similar criteria for crosssectional studies are not available. The overall rating is a
combination of internal and external validity scores. When
reviewers disagreed, a final rating was reached through
consensus. Studies reporting several different outcomes may
have different quality ratings for each outcome depending on
how completely it controlled for key confounders in multivariable models.

to adjust or stratify for potentially important variables such as
age, race, BMI, life events, or history of depression when
attempting to attribute symptoms to change in menopausal
stage. Although most included studies were population-based,
in many cases, enrolled women were additionally selected from
the initial recruited cohort and may have been less
representative of the general population. Also, many studies
were based on cohorts recruited from community populations
and are more representative of volunteers than entire
communities.
Key Question 1. What is the evidence that the symptoms
more frequently reported by middle-aged women are
attributable to ovarian aging and senescence?
•

Vasomotor symptoms: Evidence from population-based
cohort and cross-sectional studies supports the association
between vasomotor symptoms and menopausal stage.
Studies are consistent in reporting increasing prevalence
rates of vasomotor symptoms as women transition from
premenopause to either perimenopause or postmenopause,
affecting 50 percent or more of women. Studies suggest
that vasomotor symptoms persist for several years after
menopause for some women.

•

Vaginal dryness: Vaginal dryness is associated with
menopause and prevalence rates increase as women
transition through the menopausal stages. Estimates
indicate that up to one third of perimenopausal and
postmenopausal women experience vaginal dryness.

•

Sleep disturbance: Although results of studies are mixed,
two good-quality cohort studies indicate that women have
more difficulty sleeping as they transition through
menopausal stages, and this may be due to vasomotor
symptoms. Up to 40 percent to 60 percent of
perimenopausal and postmenopausal women experience
sleep disturbance, a slight increase from prevalence rates of
premenopausal women.

•

Mood symptoms: The majority of studies from a large
literature report no associations between menopausal stage
and mood symptoms, development of a mental disorder,
or general mental health. Studies of prevalence rates
report wide ranges that are similar across menopausal
stages.

•

Cognitive disturbances: No cohort studies are available.
Cross-sectional studies indicate no difference in
forgetfulness, memory, or concentration.

•

Somatic complaints: Most studies report no association of
somatic symptoms with menopause, although somatic
symptoms were increased among perimenopausal women

Size of Literature
A total of 10,059 unique citations were reviewed, including
6,342 about symptoms and factors influencing them (Key
Questions 1 and 2); 4,078 about therapies (Key Question 3);
and 806 about specific characteristics that may influence the
effects of therapies (Key Question 4).

Results
To address Key Questions 1 and 2, the review focused on
prospective studies of cohorts of midlife women transitioning
through the stages of menopause. Forty-eight studies
conducted among 14 cohorts met inclusion criteria. Seven
cohorts were based in the United States (Massachusetts
Women’s Health Study, Seattle Midlife Women’s Health Study,
Ohio Midlife Women’s Study, National Health Examination
Follow-up Study [NHANES], Study of Women’s Health Across
the Nation [SWAN], University of Minnesota/Tremin Trust
Longitudinal Study, and Pennsylvania Ovarian Aging Study).
Seven cohorts were based outside the United States
(Gothenburg, Sweden, Australian Longitudinal Study on
Women’s Health, Medical Research Council [MRC], U.K.,
Melbourne Women’s Midlife Health Project, Australia,
Manitoba Project on Women and Their Health in the Middle
Years, Canada, Copenhagen, Denmark, and Eindhoven,
Netherlands). An additional 22 cross-sectional studies from
other populations meeting similar inclusion criteria were
obtained to provide additional prevalence data.
Major limitations of studies include dissimilar methods for
evaluating and reporting symptoms and for assessing
menopausal change. Some cohort studies based results on
cross-sectional data reported at serial time points rather than
individual tracking of women over time. Some studies failed

3

compared with premenopausal women in one cohort and
two cross-sectional studies.
•

Urinary complaints: Urinary leakage increased among
perimenopausal women compared with premenopausal
women in one study, and another reported no
associations. Studies of prevalence rates report wide
ranges that are similar across menopausal stages.

•

Uterine bleeding problems: No studies meeting inclusion
criteria addressed uterine bleeding problems, most likely
because currently accepted definitions of menopause rely
historically on changes in uterine bleeding.

•

Sexual dysfunction: Women from one study cohort
reported declines in some or all of the measured sexual
parameters as they transitioned through menopausal
stages. Results of cross-sectional studies are mixed.

•

Reduced quality of life: Results of available cohort and
cross-sectional studies are conflicting.

Key Question 3. What is the evidence for the benefits and
harms of commonly used interventions for relief of menopauserelated symptoms?
•

A total of 192 randomized controlled trials of therapies for
managing menopause-related symptoms were evaluated,
including trials of estrogens, progestins, androgens
(testosterone and DHEA [dehydroepiandrosterone]),
tibolone, antidepressants (selective serotonin reuptake
inhibitors, moclobemide, veralipride), other drugs
(clonidine, methyldopa, gabapentin, Bellergal),
phytoestrogens (dietary and extract forms of soy
isoflavones, other forms of phytoestrogen, combinations),
complementary and alternative medicine (acupuncture,
Chinese herbs, red clover, black cohosh, combinations,
other types of supplements, manual therapies, energy
therapies), and behavioral interventions (exercise and other
types of interventions).

•

Estrogen, in either opposed or unopposed regimens, is the
most consistently effective therapy for vasomotor
symptoms, and demonstrates benefit in most trials
evaluating urogenital symptoms. Some, but not all, trials
evaluating sleep, mood and depression, sexual function,
and quality of life outcomes also report benefit with
estrogen compared to placebo.

•

Breast tenderness and uterine bleeding are the most
commonly reported adverse outcomes in estrogen trials;
others include nausea and vomiting, headache, weight
change, dizziness, venous thromboembolic events,
cardiovascular events, rash and pruritus, cholecystitis, and
liver effects.

Key Question 2. When do the menopausal symptoms
appear, how long do they persist and with what frequency and
severity, and what is known about the factors that influence
them?
•

Included studies do not provide adequate details to
characterize the onset, severity, and duration of specific
symptoms. Frequency is described by prevalence data in
Key Question 1.

•

Race and ethnicity: The influence of race and ethnicity on
menopausal symptoms has not been extensively studied.
Prevalence rates of vasomotor and mood symptoms vary
among race and ethnic groups in the large SWAN cohort.

•

Age at onset of menopausal transition: Available studies are
inconclusive.

•

Trials of progestin indicate mixed results for treatment of
vasomotor symptoms.

•

Body mass index: Available studies are inconclusive.

•

•

Surgical versus natural menopause: Studies present mixed
results regarding the impact of surgical menopause on
vasomotor symptoms, vaginal dryness, and mood.
Adjustment for confounders is necessary because women
undergoing hysterectomy differ from women with natural
menopause in ways that may also influence their
menopause related symptoms.

Few trials of testosterone are available; one trial indicated
no differences between testosterone/estrogen and estrogen
alone for hot flash severity, vaginal dryness, or sleep
problems. Sexual symptoms were improved with
testosterone/estrogen compared to estrogen alone or
placebo in two other trials.

•

For women using testosterone combined with estrogen,
acne and hirsutism occur significantly more often than for
women using estrogen alone.

•

Based on only a few fair or good-quality trials, tibolone
demonstrated benefit for vasomotor symptoms, sleep, and
somatic complaints compared to placebo, and was similar
to estrogen for some, but not all, symptoms.

•

Uterine bleeding, body pain, weight gain, and headache
were more common in tibolone vs. placebo groups.

•

•
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Depression: One cross-sectional study reported that prior
anxiety or depression did not predict menopausal
symptoms. Cohort studies show that a history of
depression predicts depression in the menopausal
transition. No studies evaluated depression in associaton
with other menopausal symptoms.
Smoking: Available studies are inconclusive.

•

•

Several agents demonstrate benefits in managing
vasomotor symptoms in some, but not all trials, or in only
a few available trials, including paroxetine, veralipride,
gabapentin, soy isoflavones, and other phytoestrogens.
Trials of soy isoflavones and other complementary and
alternative medicine therapies report benefits in improving
nonvasomotor symptoms, although results vary widely,
methods are lacking, and studies are typically small and
not generalizable.

•

Placebo effects in trials are large reflecting underlying
fluctuations of symptoms.

•

Although benefits and adverse effects of therapies were
equally important in this review, most trials did not report
adverse effects or reported them incompletely.

Key Question 4. What are the important considerations in
managing menopause-related symptoms in women with clinical
characteristics or circumstances that may complicate decisionmaking?
•

Evidence is not available to determine if the effectiveness
of therapy for menopause related symptoms or adverse
effects differ for women with bilateral oophorectomy,
premature ovarian failure, concurrent use of SERMs or
other potentially interacting agents, lifestyle and
behavioral factors, recent discontinuation of menopausal
hormone therapy, or very low or very high BMI.

•

For women with breast cancer, results of 15 randomized
controlled trials indicate that clonidine, venlafaxine, and
megestrol acetate are associated with significantly
improved measures of hot flashes, and vitamin E, black
cohosh, isoflavones, magnets, and fluoxetine are not.
Results for nonvasomotor outcomes are mixed.

Key Question 5. What are the future research directions for
treatment of menopause-related symptoms and conditions?
In order to fill evidence gaps, future research could focus on:

•

Better reporting of adverse effects in trials and use of
standardized categories of adverse effects so data can be
combined across trials.

•

Improved analysis of results including analysis by
hysterectomy and oophorectomy status, stage of
menopause, age, concurrent conditions and medications,
and other factors.

•

More comprehensive trials to determine the role of regular
exercise, sleep management, optimal nutrition, healthy
relationships, social support, and relaxation; effects of
mind-body techniques such as biofeedback and breathing;
effects of a whole system approach with Chinese medicine.

•

Additional, well-designed and controlled trials of
phytoestrogens, botanicals, and bio-identical hormones,
especially estriol, estradiol, and progesterone. Further
study of antidepressants for vasomotor symptoms would
be justified based on evidence of currently available trials.

•

Enrollment of women with specific characteristics who
have not previously been evaluated such as nonwhite
women, women with premature ovarian failure, those
using SERMs and other agents influencing symptoms
concurrently, women with very high or low BMI, and
those with lifestyle and behavioral factors influencing
symptoms. Trials should report data specific to these
groups in order to interpret their influence on therapy.

•

Use of standard definitions, measures, outcomes, and
statistical methods for longitudinal data so results can be
compared across trials and population cohorts.

•

Prevalence data in U.S. women.

•

Details about onset, timing, and duration of symptoms in
relation to menopausal stage.

•

Studies of symptoms after surgical menopause with and
without hormonal therapy.

•

Determination of optimally effective doses, combination
regimens, durations of use, and timing of therapy.

Conclusions

•

Evaluation of approaches to identify optimal candidates
for specific therapies (e.g., identification of
thrombophilias).

•

Head-to-head and placebo comparisons of estrogen alone
and combined with other types of therapies including non
drug interventions.

•

Trials demonstrating how to discontinue estrogen when
symptoms subside, including the effectiveness of tapering
doses and/or replacing with other therapies including non
drug interventions.

Based on review of currently available cohort and crosssectional population studies, vasomotor symptoms and vaginal
dryness are symptoms most consistently associated with the
menopausal transition. Sleep disturbance, somatic complaints,
urinary complaints, sexual dysfunction, mood, and quality of
life are inconsistently associated. No cohort studies provide
data on cognition, but cross-sectional studies suggest no
association. There are no studies about uterine bleeding
problems, onset, duration, and severity of specific symptoms, or
conclusive data on the influence of race/ethnicity, age of onset
of menopause, BMI, oophorectomy status, presence of
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depression, or smoking status. The literature is limited by
differences in how symptoms are defined and measured,
variability of study populations, and incompatibility of data
preventing direct comparisons between studies or pooling of
results. Future research using standard and validated measures
and uniform definitions for a more comprehensive array of
symptoms would improve knowledge of these associations.
Trials of therapy are conclusive only for estrogen and its use
in treating vasomotor and urogenital symptoms, although other
therapies may prove effective if further studied. Undertaking
trials to treat symptoms that are not clearly associated with the
menopausal transition would not be useful. Trials are limited in
many ways including use of highly selected small samples of
women; short durations; inadequate reporting of loss to follow
up, maintenance of comparable groups, contamination,
methods of analysis, and adverse events; use of dissimilar
measures and outcomes that are often not standardized or
validated; unclear inclusion and exclusion criteria; and industry
sponsorship. Future research addressing these deficiencies, as
outlined in Key Question 5, would guide patient and clinician
decision making when managing menopause related symptoms.
The evidence review is limited in several ways. For Key
Questions 1 and 2, literature searches focused on population
studies of women undergoing the menopausal transition
reporting symptoms, and did not include epidemiologic or
biologically-based etiologic studies. In addition, studies that
may not have been identified by searches include those in
which menopause was not a primary focus of the study, but a
predictor variable included in a multivariable model evaluating
the outcome or symptom of interest. Studies potentially not
identified would be those that identified no association between
menopausal stage and the outcome of interest. Studies with a
positive association would probably have reported it in the
abstract and be identified by the searches. Also, the review was
limited to English-language randomized controlled trials of
therapies. Exploratory studies of agents may provide
contributory data that were not included in this report.

Center, under Contract No. 290-02-0024. It is expected to be
available in March 2005. At that time, printed copies may be
obtained free of charge from the AHRQ Publications
Clearinghouse by calling 800-358-9295. Requesters should ask
for Evidence Report/Technology Assessment No. 120,
Management of Menopause-Related Symptoms. In addition,
Internet users will be able to access the report and summary
online through AHRQ’s Web site at www.ahrq.gov.
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